ADHD Clinical Trials 2024

ADHD Clinical Trials 2024

ADHD research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in ADD clinical trials today.

ADHD Clinical Trials

Here are the 6 most popular medical studies for adhd

Las Vegas, Nevada

Central Nervous System Stimulant

Aptensio XR for Attention Deficit Hyperactivity Disorder (ADHD)

Recruiting4 awardsPhase 4
Las Vegas, Nevada

The primary objective of this study is to evaluate the long-term safety and tolerability of methylphenidate hydrochloride extended-release capsules (Aptensio XR®) in children aged 4-5 years who have been diagnosed with attention-deficit/hyperactivity disorder (ADHD). Safety and tolerability will be evaluated by assessing treatment-emergent adverse events (TEAEs) blood pressure, pulse, height, weight, electrocardiograms (ECGs), laboratory The primary objective of this study is to evaluate the long-term (12-month) safety and tolerability of Aptensio XR® in children aged 4 to less than 6 years who have been diagnosed with ADHD. Safety and tolerability will be evaluated by assessing treatment-emergent adverse events (TEAEs) blood pressure, pulse, height, weight, electrocardiograms (ECGs), laboratory values and Columbia Suicide Severity Rating Scale (C-SSRS). Disturbances in sleep (quantity and quality) patterns will also be assessed using the Child Sleep Habits Questionnaire (CSHQ). Secondary objectives include assessment of long-term efficacy of Aptensio XR®. Secondary measures include: Investigator administered Attention-Deficit/Hyperactivity Disorder Rating Scale Preschool Version (ADHD-RS-IV Preschool Version) Clinical Global Impressions-Severity Scale (CGI-S ) Connors Early Childhood Behavior-Parent Short form [Conners EC BEH-P(S)]

Popular filter options for adhd trials

Attention Deficit Hyperactivity Disorder (ADHD) Clinical Trials

View 85 Attention Deficit Hyperactivity Disorder (ADHD) medical studies.

Charlottesville, Virginia

Behavioural Intervention

Behavioral contingency management +1 More for Attention Deficit Hyperactivity Disorder (ADHD)

Recruiting1 award2 criteria
Charlottesville, Virginia

Children with Attention-Deficit/Hyperactivity Disorder (ADHD) comprise about 5-10% of the elementary school-age population. One place where children with ADHD have great difficulty is in being accepted by peers and in making friends. It has unfortunately been very difficult for the field to find good treatments for peer relationship problems for this population. Even when children with ADHD do improve their behavior, it is common that peers do not seem to like the child with ADHD any better. This may happen because children often have negative reputations with their classmates that are hard to change. That is, once a class of children get the impression that one child is disliked or the social outcast, even if that child's ADHD symptoms get better, the peer group may not notice any of these improvements. It is hypothesized that the elementary school teacher may be able to help peers notice positive behavior changes in children with ADHD when they do occur. This clinical trial will design and pilot-test an intervention that would train teachers in classroom practices to reduce the peer rejection of students with ADHD. The pilot test will be conducted in a summer program created to be similar to a regular school classroom in structure. If the treatment seems to succeed in the summer program, then it will be tried in regular classrooms in a future study.
Long Island City, New York

Behavioural Intervention

Shared Care for Attention Deficit Hyperactivity Disorder (ADHD)

Recruiting1 award7 criteria
Long Island City, New York

Due to the shortage of child psychiatrists and the high prevalence of child mental health disorder, pediatricians and other pediatric primary care providers often assume responsibility for the management of various psychiatric disorders, including ADHD, Attention Deficit Hyperactivity Disorder. However, pediatricians have not been well-trained during residency to deal with the complexities of ADHD management. In addition, the system of care under which pediatricians practice do not afford the time availability that is required to properly manage a child with ADHD. On the other hand, if a pediatrician wishes to refer a patient to a child mental health specialist, many obstacles, including but not limited to stigma, insurance issues, and long waiting lists, often interfere with the patient actually receiving services for his/her ADHD. This research project seeks to examine an innovative model of care in which a child psychologist is located on the premises of a pediatric office and is available to share the care of patients with the pediatrician in order to address ADHD. We hypothesize that parents as well as pediatricians will be more satisfied with this model of care and that patients will ultimately have better outcomes. The beginning of our pilot has shown under-identification to be a barrier to care as well, and thus we propose to implement a quality improvement initiative to screen children for psychosocial issues as well. As we have had trouble with recruitment and unfortunately have had more children randomized to TAU than shared care, we propose in December 2007 a phase 2 of our study where all subjects, instead of randomization, are entered into shared care.

Attention Deficit Disorder Clinical Trials

View 85 Attention Deficit Disorder medical studies.

Charlottesville, Virginia

Behavioural Intervention

Behavioral contingency management +1 More for Attention Deficit Hyperactivity Disorder (ADHD)

Recruiting1 award2 criteria
Charlottesville, Virginia

Children with Attention-Deficit/Hyperactivity Disorder (ADHD) comprise about 5-10% of the elementary school-age population. One place where children with ADHD have great difficulty is in being accepted by peers and in making friends. It has unfortunately been very difficult for the field to find good treatments for peer relationship problems for this population. Even when children with ADHD do improve their behavior, it is common that peers do not seem to like the child with ADHD any better. This may happen because children often have negative reputations with their classmates that are hard to change. That is, once a class of children get the impression that one child is disliked or the social outcast, even if that child's ADHD symptoms get better, the peer group may not notice any of these improvements. It is hypothesized that the elementary school teacher may be able to help peers notice positive behavior changes in children with ADHD when they do occur. This clinical trial will design and pilot-test an intervention that would train teachers in classroom practices to reduce the peer rejection of students with ADHD. The pilot test will be conducted in a summer program created to be similar to a regular school classroom in structure. If the treatment seems to succeed in the summer program, then it will be tried in regular classrooms in a future study.
Long Island City, New York

Behavioural Intervention

Shared Care for Attention Deficit Hyperactivity Disorder (ADHD)

Recruiting1 award7 criteria
Long Island City, New York

Due to the shortage of child psychiatrists and the high prevalence of child mental health disorder, pediatricians and other pediatric primary care providers often assume responsibility for the management of various psychiatric disorders, including ADHD, Attention Deficit Hyperactivity Disorder. However, pediatricians have not been well-trained during residency to deal with the complexities of ADHD management. In addition, the system of care under which pediatricians practice do not afford the time availability that is required to properly manage a child with ADHD. On the other hand, if a pediatrician wishes to refer a patient to a child mental health specialist, many obstacles, including but not limited to stigma, insurance issues, and long waiting lists, often interfere with the patient actually receiving services for his/her ADHD. This research project seeks to examine an innovative model of care in which a child psychologist is located on the premises of a pediatric office and is available to share the care of patients with the pediatrician in order to address ADHD. We hypothesize that parents as well as pediatricians will be more satisfied with this model of care and that patients will ultimately have better outcomes. The beginning of our pilot has shown under-identification to be a barrier to care as well, and thus we propose to implement a quality improvement initiative to screen children for psychosocial issues as well. As we have had trouble with recruitment and unfortunately have had more children randomized to TAU than shared care, we propose in December 2007 a phase 2 of our study where all subjects, instead of randomization, are entered into shared care.

Phase 3 Adhd Clinical Trials

View 87 phase 3 adhd medical studies.

Adhd Clinical Trials With No Placebo

View 87 adhd medical studies that do not have a placebo group.

Charlottesville, Virginia

Behavioural Intervention

Behavioral contingency management +1 More for Attention Deficit Hyperactivity Disorder (ADHD)

Recruiting1 award2 criteria
Charlottesville, Virginia

Children with Attention-Deficit/Hyperactivity Disorder (ADHD) comprise about 5-10% of the elementary school-age population. One place where children with ADHD have great difficulty is in being accepted by peers and in making friends. It has unfortunately been very difficult for the field to find good treatments for peer relationship problems for this population. Even when children with ADHD do improve their behavior, it is common that peers do not seem to like the child with ADHD any better. This may happen because children often have negative reputations with their classmates that are hard to change. That is, once a class of children get the impression that one child is disliked or the social outcast, even if that child's ADHD symptoms get better, the peer group may not notice any of these improvements. It is hypothesized that the elementary school teacher may be able to help peers notice positive behavior changes in children with ADHD when they do occur. This clinical trial will design and pilot-test an intervention that would train teachers in classroom practices to reduce the peer rejection of students with ADHD. The pilot test will be conducted in a summer program created to be similar to a regular school classroom in structure. If the treatment seems to succeed in the summer program, then it will be tried in regular classrooms in a future study.
Long Island City, New York

Behavioural Intervention

Shared Care for Attention Deficit Hyperactivity Disorder (ADHD)

Recruiting1 award7 criteria
Long Island City, New York

Due to the shortage of child psychiatrists and the high prevalence of child mental health disorder, pediatricians and other pediatric primary care providers often assume responsibility for the management of various psychiatric disorders, including ADHD, Attention Deficit Hyperactivity Disorder. However, pediatricians have not been well-trained during residency to deal with the complexities of ADHD management. In addition, the system of care under which pediatricians practice do not afford the time availability that is required to properly manage a child with ADHD. On the other hand, if a pediatrician wishes to refer a patient to a child mental health specialist, many obstacles, including but not limited to stigma, insurance issues, and long waiting lists, often interfere with the patient actually receiving services for his/her ADHD. This research project seeks to examine an innovative model of care in which a child psychologist is located on the premises of a pediatric office and is available to share the care of patients with the pediatrician in order to address ADHD. We hypothesize that parents as well as pediatricians will be more satisfied with this model of care and that patients will ultimately have better outcomes. The beginning of our pilot has shown under-identification to be a barrier to care as well, and thus we propose to implement a quality improvement initiative to screen children for psychosocial issues as well. As we have had trouble with recruitment and unfortunately have had more children randomized to TAU than shared care, we propose in December 2007 a phase 2 of our study where all subjects, instead of randomization, are entered into shared care.

View More Adhd Trials

See another 66 medical studies focused on adhd.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to adhd

What are the top hospitals conducting adhd research?

In the realm of ADHD research and clinical trials, several hospitals have emerged as key players in advancing our understanding and treatment of this condition. Massachusetts General Hospital, located in Boston, leads the way with six ongoing ADHD trials and an impressive track record of 33 completed studies since their initial foray into ADHD research in 2001. Across the Atlantic, Hassman Research Institute based in Berlin has become a vital hub for ADHD trials as well. Though relatively new to the field with just four active trials and six overall studies since 2019, their dedication is undeniable.

Meanwhile, Alivation Research LLC located in Lincoln stands out with four active ADHD trials currently underway alongside seven previously conducted ones from their first recorded trial back in 2015. In Cincinnati's medical landscape, another institution making significant strides is Cincinnati Children's Hospital Medical Center where they boast involvement in four ongoing clinical tests alongside seventeen accomplished investigations dating back earlier to2003.The Seattle Children's Hospital also plays a crucial role within this sphere; while conducting three active ADHD trials at present it’s indeed noteworthy that theirs can be traced all the way back solely over eleven years ago to2009.

These hospitals signify not only breakthroughs but hope towards providing effective solutions for individuals affected by Attention Deficit Hyperactivity Disorder (ADHD). The collective efforts displayed among these leading institutions demonstrate unwavering commitment to unlocking greater insights into this neurodevelopmental disorder which affects millions worldwide. With each study undertaken comes potential advancements that could shape improved management strategies and brighter futures for those living with ADHD

Which are the best cities for adhd clinical trials?

When it comes to ADHD clinical trials, several cities have emerged as key players in the research field. Las Vegas, Nevada leads the pack with 12 active trials focusing on treatments like SPN-812 and Guanfacine hydrochloride (TAK-503). New york, New York follows closely behind with 10 ongoing studies examining therapies for adult ADHD patients such as centanafadine capsule. Boston, Massachusetts has 9 active trials investigating interventions like SMS Intervention and Solriamfetol 150 mg. Additionally, Cincinnati, Ohio is conducting 8 trials exploring treatments including Atomoxetine and Guanfacine hydrochloride (TAK-503), while Jacksonville, Florida offers 7 trials studying various ADHD therapies. These cities provide individuals with ADHD opportunities to participate in cutting-edge clinical research that could drive advancements in treatment options and improve quality of life.

Which are the top treatments for adhd being explored in clinical trials?

Exciting advancements are being made in the exploration of top treatments for ADHD through ongoing clinical trials. One notable intervention is SMS Intervention, which is currently being tested in three active trials and has a total of three ADHD trials since its initial listing in 2016. Additionally, there are two active trials investigating the effectiveness of ADHD Therapy, a treatment that entered the scene in 2023. Another intriguing avenue being explored is Tai Chi, with two active trials underway since its introduction to ADHD research in 2016. Finally, it's worth mentioning methylphenidate—a well-established player—which continues to show promise with two ongoing studies and an impressive track record of forty all-time ADHD trials dating back to 1998. As researchers delve deeper into these approaches, new possibilities may emerge for individuals affected by ADHD.

What are the most recent clinical trials for adhd?

Recent clinical trials have provided promising prospects for individuals with ADHD, offering potential advancements in treatment and care. Among these trials is the exploration of an experimental medication called CTx-1301, specifically a 37.5mg dexmethylphenidate tablet. The study aims to evaluate its efficacy in managing symptoms associated with ADHD, bringing hope to those seeking effective pharmaceutical interventions. Furthermore, another trial investigates the use of solriamfetol at a dose of 150 mg as a potential treatment option for ADHD patients. By delving into these innovative approaches through rigorous phases of testing, researchers aim to improve the lives and well-being of individuals living with this condition.

What adhd clinical trials were recently completed?

In the realm of ADHD research, recent clinical trials have reached significant milestones, bringing us closer to improved treatments for this neurodevelopmental disorder. In August 2021, Massachusetts General Hospital successfully completed a trial investigating the effectiveness of Solriamfetol 75 MG in managing ADHD symptoms. Similarly, Otsuka Pharmaceutical Development & Commercialization accomplished a trial testing Centanafadine in March 2021. These advancements highlight the commitment of researchers to finding novel solutions for individuals with ADHD and hold promise for enhancing their quality of life.